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Conclusions: RF ablation for VT occurring in pts with SHD without ICD
appears safe and efficient and might be now proposed as an alternative for
ICD implantation because of associated morbidity, advanced age or when VT
is well tolerated and does not occur in the context of advanced heart disease.
200
Safety of transvenous pulmonary vein isolation for the treatment of
atrial fibrillation:
a prospective randomized study comparing radiofrequency energy
with cryoenergy 
Claudia Herrera Siklody (1), Laurence Jesel (2), Dietmar Trenk (1), Chris-
tian Stratz (1), Christian M. Valina (1), Reinhold Weber (1), Jan Minners
(1), Dietrisch Kalusche (1), Florence Toti (3), Olivier Morel (4), Thomas
Arentz (1)
(1) Herzzentrum, Bad Krozingen, Allemagne - (2) Hôpitaux Universitaires
de Strasbourg, Strasbourg, France - (3) INSERM 770 et Université de
Strasbourg, Strasbourg, France - (4) Pôle d'activité médico-chirurgicale
cardiovasculaire, NHC, Strasbourg, France
Background: New transvenous devices using cryoenergy have been
recently introduced to perform pulmonary vein isolation (PVI) for the treat-
ment of atrial fibrillation (AF). Experimental data suggested that cryoenergy
(CRYO) produced less endothelial disruption and platelet activation than
radiofrequency energy (RF) offering safety benefits. We aimed to compare
both systems with regards to safety in patients by measuring for the first time
sensitive laboratory markers of cell damage. platelet activation and inflamma-
tion after a PVI using either one of those energies.
Methods: Sixty patients with symptomatic drug-resistant AF referred for
PVI (56±9 years of age, 48 males. 38 with paroxysmal and 22 with persistent
AF) were randomly assigned to undergo the ablation procedure using either an
open irrigated tip RF catheter (Thermocool®. Biosense Webster) or a cryobal-
loon catheter (Arctic front®. Medtronic). Systemic markers of cell damage
(procoagulant microparticles [MPs of various cellular origin], troponin T, CK
and CK-MB). platelet activation (ADP-induced light transmittance aggrega-
tion [LTA], expression of the platelet surface proteins P-selectin [pSEL] and
activated GPIIb/IIIa [PAC-1]) and inflammatory response (hs-CRP) were
determined frequently before and 4, 24 and 48 hours  after the procedure.
Results: Procedure time was significantly shorter in patients treated with
the cryoballoon (177±30 min versus 200±46 min. p=0.028), but there were no
differences in fluoroscopic time, clinical event rate and success rate.  Post-pro-
cedural increases of MPs Troponin T and hs-CRP were observed but there
were no consistent differences in parameters used for comparative laboratory
safety assessment of the ablation systems using either cryoenergy or radiofre-
quency energy.
Conclusions: Neither systematic sensitive markers of cell damage, of
platelet activation nor of inflammatory response could detect any difference in
the safety profile between cryoenergy and RF energy used for transseptal PVI
in patients with AF.
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Introduction: Radiofrequency (RF) catheter ablation has emerged as an
effective treatment for patients with drug-refractory atrial fibrillation (AF).
The objective of this study is to evaluate the efficacy and safety of pulmonary
vein isolation (PVI) with a cryoballoon catheter (Arctic Front, Cryocath,
Quebec, Canada). 
Methods: In 44 consecutive patients with symptomatic paroxysmal AF (28
males, age 57+/-11 years), circumferential PVI was performed using a cry-
oballoon catheter. Before discharge, all patients were subjected to 24-hour
Holter electrocardiograms, echocardiography, and esophageal endoscopy.
Magnetic resonance imaging was performed prior to and 3 months after abla-
tion.  At a mean follow up of 4.3 +/- 1.2 months after ablation, patients under-
went clinical review and 24-hour Holter electrocardiograms. Clinical and
demographic variables were analyzed via logistic regression to assess for pre-
dictors of recurrence. 
Results: Thirty-two of the 44 patients (73%) had complete isolation of all
PVs.  Out of 176 treated veins, 164 were completely isolated (93%). The
number of balloon applications per vein was 2.3 ± 0.8. The mean procedure
and fluoroscopy times were 163.4 ± 36.2 and 32.0 ± 11.7 min, respectively.
Eight patients had evidence of mild pericardial effusions requiring no further
treatment.  Five patients (11.4%) experienced phrenic nerve palsy, 4 of which
resolved immediately and one at 2 weeks.  Follow up at 4.3 +/- 1.2 months
showed freedom from AF in 28 patients (63.6%) and freedom from AF
without antiarrhythmic drug therapy in 19 patients (43.2%).  Of all clinical
variables analyzed, only early recurrence of AF within 4 days post ablation
was associated with long term AF recurrence (p= 0.002; OR= 0.11; CI=
[0.018-0.524]). 
Conclusion: PVI can be safely achieved with the cryoballoon catheter with
a moderate success rate at 4.3 months follow-up. Early recurrence of AF
seems to be a clinical predictor for long term atrial fibrillation recurrence.
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Background: Radiofrequency ablation [RFA] of outflow tract ventricular
ectopic beats [OTVEBs] can be performed using either a 4 mm or an exter-
nally-cooled tip RFA catheter but not data are available concerning the safety
and the efficacy with a large-tip [8 mm] catheter. However, experimental and
clinical studies suggest that the efficacy of catheters may vary mainly with
several parameters including catheter tip, cooling effect, anatomy and catheters
orientation. We hypothesized that an 8mm tip catheter can be safely used in
patients with OTVEBs. 
Objectives: The aim of this prospective study was to evaluate the safety
and the efficacy of an 8mm tip catheter in patients with OTVEBs. 
Method and Results: Between September 2008 and March 2010, 17
patients were referred for RFA of symptomatic OTVEBs and 2 patients were
excluded [1 cardiomyopathy and 1 due to the vicinity of His bundle]. In a pri-
mary intent the 8mm tip catheter was tested. Population characteristics were as
follows: mean age of 51±17 years; 46.7% female; LVEF (55±8%); VEB mor-
phology [100% LBBB], axis [13 inferior and 2 superior], major symptoms
[palpitations in 7, pre-syncope in 6, syncope in 1, and dyspnea in 1], VEB
width 144±21 ms, and number of drug failure [2.2±0.5]. RFA succeeded
in 14/15 patients [93.3%] and RFA parameters were: procedure time [94±35
min], duration of application [11±10 min], impedance [81±12 ], temperature
[48±5 degree] and power [46±17 watts]. In one patient RFA failed. Recur-
rence occurred in 1/15 patients [6.6%] with a mean follow-up of 8±6 months.
No complication was observed. 
Conclusions: This study demonstrated the feasibility, safety and efficacy
of a strategy with an 8mm tip RFA catheter to cure patients with outflow tract
ventricular ectopic beats.
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